Insulet data shows Omnipod 5's superiority to regular pump therapy
WEBMar 8, 2024 · Insulet’s OP5-003 trial set out to evaluate Omnipod 5 in a population representative of the real world. Primarily, that applied to participants with an HbA1c above 8% at baseline. The company presented data for 194 adults who used traditional (non-AID) therapy. That included 87% using previous-generation Omnipod or Omnipod Dash …
Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S.
WEBJun 20, 2024 · Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM. It proactively corrects for highs and protects against lows with insulin dosing. The waterproof device features mobile app control for ease of use. Acton, Massachusetts-based Insulet began a limited rollout of Omnipod 5 with G7 earlier …
i2o looks to revive diabetes drug-eluting implant from Intarcia
WEBSep 5, 2023 · i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics. The Boston-based company acquired and integrated Intarcia’s proprietary assets and made a big personnel move. With CEO Ravi Srinivasan moving onto other opportunities, i2o named Kurt Graves as chair, president …
Vaxess raises $9M to support shelf-stable vaccine patch
WEBSep 13, 2023 · Vaxess Technologies announced today that it raised an additional $9 million in venture capital funding to support its vaccine delivery technology. Cambridge, Massachusetts-based Vaxess develops a shelf-stable vaccine patch with the potential for self-application. The company’s MiMix system features sustained-release technology for ...
FDA approves next-gen drug delivery system from Medtronic
WEBOctober 10, 2023 By Sean Whooley. The SynchroMed III system. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) announced today that the FDA approved its next-generation SynchroMed III intrathecal drug delivery system. The medtech giant designed SynchroMed III to treat patients with chronic pain, cancer pain and severe spasticity.
Focus collaborates with Glucotrack on implantable CBGM
WEBJuly 15, 2024 By Sean Whooley. Focus recently announced that it entered into a collaboration with Glucotrack to develop an implantable continuous blood glucose monitor (CBGM). The company said in a LinkedIn post that it expects the long-term, implantable technology to transform how people with diabetes interact with their condition.
Medtronic wins CE mark for MiniMed 780G with Simplera Sync
WEBJan 8, 2024 · The MiniMed 780G with the Simplera Sync CGM and accompanying devices. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) announced today that it received CE mark approval for its MiniMed 780G system with Simplera Sync. Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM), eliminates the need for …
Dexcom announces direct-to-watch feature for G7 CGM
WEBMar 5, 2024 · The ONE+ system, featuring a sensor, reader, smartphone, smartwatch and applicator. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. The company plans a phased launch for all G7 iOS users everywhere by the end …
Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
WEBDec 28, 2021 · Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed.. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo …
Medtronic wins Canadian nod for Guardian 4 use with insulin pump
WEBMay 4, 2023 · MiniMed 780G with Guardian 4 offers insulin to account for when users forget to bolus or underestimate the number of carbs in their meal. Medtronic expects to launch the new sensor in Canada by the end of 2023. Canadian officials previously approved the MiniMed 780G pump in November 2022. “With the recent launch of the world’s first and ...